Editorial: Updates on the management of glioblastoma

Glioblastoma (GBM) is the most common and malignant primary brain tumour with an extremely poor median survival time of only 15 months and a dismal 5-year survival of just 7.2% (Kanderi et al., 2024). The significant therapeutic challenge, posed by glioblastoma, stems from its genetic and phenotypic heterogeneity fueled by multiple components of the dynamic system of the tumour including treatment-resistant glioma cells and tumour microenvironment (TME). The current standard of care therapy for glioblastoma consists of surgical resection of the tumour followed by chemoradiation and adjuvant chemotherapy using an alkylating agent, temozolomide (Stupp et al., 2005). Studies published to date, demonstrate the complexity of mechanisms by which glioblastoma tumours overcome the pressure of currently established treatments allowing for post-therapy disease progression, tumour recurrence and patient relapse (Dymova et al., 2021). There is a desperate need for novel strategies in detection, diagnostics and targeted therapeutic approaches to attain successful containment of this deadly disease.The goal of this Research Topic was to consolidate and showcase studies that encompass new approaches to the management of glioblastoma. In this editorial, we highlight novel and trending directions in research based on 16 studies of the Research Topic including seven original articles, two minireviews, six reviews, and one case report. The diversity of the content reflects the necessary innovation to seek, analyze and discuss breakthrough findings to advance diagnostic tools, therapy, and specifically, immunotherapy which is the focal point of several articles in the topic and will be the context of this editorial.In recent years the importance of the TME in influencing the biology of glioblastoma has been gaining interest. To date, this has been heavily focused on the analysis of infiltrating cells of the immune system, aiding not only in the classification of the tumours but also in assessment for potential immunotherapies (Peres et al., 2024, Wang et al., 2017). In the study by Guo et al., researchers investigated the expression profile of G protein-coupled receptors (GPCRs) in glioblastoma using both publicly available tumor bulk RNA sequencing and in-house single-cell RNAseq to evaluate RNA abundance and association with the TME. The study constructed a risk model associated with GPCR expression and created a TME score, based on infiltrated immune cells. This work uncovered new survival and immune phenotypes which are marked by differential expression of GPCRs and show that patient outcomes correlate positively with GPCR/TME score. Although these results demonstrate a potential benefit in predicting disease progression, recent clinical data shows that the efficacy of immunotherapies is determined not only by the immunogenicity of the tumour but also by the baseline systemic immunological competence of a patient, which remains to be considered in this model.Interpatient heterogeneity in immunosuppressive activity is reflected in variable dysregulation of diverse components of the immune system including a decrease in T lymphocytes (lymphopenia) or changes in the neutrophil-to-lymphocyte ratio. Assessment of the absolute counts, ratios and activation states of both circulating as well as tumour-infiltrating immune cells result in differences in the responses to therapy, tumour progression, recurrence and survival (Vitale et al., 2021). Tumour-related immunosuppression is further exacerbated by the standard of care, including radio-and chemo-therapy which leads to immunodeficiency in patients with glioblastoma resulting in therapy-induced (iatrogenic) systemic immunosuppression. In the face of failed attempts to identify a reliable prognostic immune marker over the years, two reviews in our Research Topic discuss the prognostic value and critical role of assessing diverse immune system components both at baseline and post-therapy in patients with glioblastoma. Stepanenko et al. calls for incorporation of dynamic assessment of blood inflammatory markers and parameters, including neutrophil-to-lymphocyte ratio (NLR), and post-treatment total lymphocyte count (TLC) as well as steroid use, in neuro-oncology studies and careful evaluation regarding their prognostic significance. Analysis of existing results on standard therapy-promoted immunotoxicity, in another review-"Systemic and local immunosuppression in glioblastoma and its prognostic significance", by Stepanenko et al., shows that post-therapy lymphopenia is a prognostic marker for shorter survival in patients with glioblastoma. In addition, collected data demonstrates that radiation-induced decrease in lymphocyte count is exacerbated by treatment using corticosteroids, which causes immunosuppression, and serves as a poor prognostic marker.The authors point to crucial clinical data to collect when designing clinical trials for immunotherapies and conclude that the improving success of immunotherapies depends on changes to the standard-of-care paradigm.Another critical component to consider is the potential role of sex-dependent biology on glioblastoma tumours. In a minireview by Jovanovich et al., researchers compiled data regarding sex-related differences in glioblastoma biology, reported over the past ten years, and studied potential correlation with pathogenesis as well as treatment response. This review highlights critical differences in mechanisms that may predict overall survival and treatment responses between males and females. This includes imaging radiomics-based signatures, DNA methylation patterns, timing of glioma-driver mutations and differences in metabolic and immune profiles.Females are characterized by a more active adaptive immune system, higher levels of CD4 + T cells, and significantly improved overall survival in comparison to males in immunotherapy clinical trials. The studies collected and reviewed by Jovanovich et al. validate the critical importance to personalize approaches and to consider male and female samples separately when profiling glioblastoma tumours.Change in contrast enhancement which is present in approximately 98% of gliomas and is related to biological processes of the tumour like hypoxia and inflammation, has aided in measuring therapeutic efficacy in patients with glioblastoma (Ellingson et al., 2017). Directly assessing responses to immunotherapies in glioblastoma is complicated by a transient inflammatory-based increase in enhancing volume determined as pseudo-progression (PsP) which must be distinguished from true tumour progression (TTP) to avoid the continuation of non-effective therapies (Rowe et al., 2018). This editorial highlights a study by Cuccarini et al. in which treatment response assessment maps (TRAMs) were employed to test application in immunotherapy. The study used dendritic cells to assess the diagnostic value of TRAMs in the distinction of PsP and TTP in glioblastoma. TRAMs exploit the principle of delayed contrast imaging which allowed the researchers to identify areas of early contrast-medium clearance, which reflected tissues of the tumour, with high sensitivity and specificity. They also distinguished these areas from areas of contrast-medium accumulation which were caused by treatment. This is the first pilot study of the application of TRAMs for immunotherapy which demonstrates that TRAMs could constitute an alternative or supplemental tool to differentiate between pseudoand true tumour progression providing early markers of therapy response.The current standard of care for glioblastoma results in poor clinical outcomes with a significant majority of patients experiencing recurrence/progression of an incurable tumour. There is an obvious need for testing therapeutic strategies which combine the most promising approaches.There is substantial effort occurring to optimize immunotherapies for glioblastoma; these works are summarized in detail along with other current treatment approaches in the general review on treatment advances in high-grade glioma by Chen et al. In their review, Bartusik-Aebisher et al. discuss the immunomodulatory functions of photodynamic therapy (PDT). PDT is a treatment based on light energy combined with a compatible drug molecule which, when photosensitized, destroys cells which absorbed it. PDT contributes to the activation and influx of immune cells, leukocytes, lymphocytes and macrophages into the tumour tissue, triggering an inflammatory response in addition to the release of antigens from damaged tumour cells. The application of PDT helps with directing the immune response towards the tumour and can be a beneficial strategy combined with standard of care and immunotherapy.A retrospective study by Wang et al. shows that delivery of low-intensity, low-frequency alternating electrical tumour-treating fields (TTFields) at the tumour site significantly improved progression-free and overall survival in this small cohort of patients. They demonstrated increased effectiveness in patients at post-tumour resection and with methylated MGMT, suggesting that addition of TTFields to the current standard of care may improve clinical outcomes of glioblastoma treatment. In addition, the evidence discussed by Chen et al. shows that the application of TTFields maintains the viability of T-cells, promotes phagocytosis of dendritic cells and synergizes with anti-PD-1 therapy in preclinical models, suggesting that the combination of TTFields and immunotherapy can potentially improve clinical outcomes in glioblastoma.In the mini review by Wang & Liu et al. protein lactylation is explored as a potential therapeutic target in the treatment of glioblastoma. Lactate metabolism and levels of lactylation in the tumour microenvironment play a role in recruitment, activation and maintenance of the components of the immune system (Colegio et al., 2014;Caslin et al., 2021). As the authors discuss, changes to the lactylation levels of specific proteins predict response to immune checkpoint inhibitors, hence combining of the modulation of the lactylation levels of certain proteins with immunotherapy could potentially benefit clinical outcomes of patients with glioblastoma.This special Frontiers Research Topic provides a snapshot of current and emerging strategies for predicting therapy response and enhancing the effectiveness of therapies for glioblastoma. While patient outcomes remain dire, research continues to evolve, teaching us more about the complex biology and clinical characteristics of this aggressive disease. Several of the studies in this issue demonstrate the ability to improve effectiveness of immunotherapy, which is currently the fastest growing field with great clinical potential for glioblastoma. This edition highlights the progress happening in the glioblastoma field. Researchers continue to pioneer ways to enhance survival rates and improve patient quality of life. The complexity of glioblastoma necessitates continued efforts to collaborate, to advocate for dedicated funding and patient-centric research to sustain and accelerate progress in this field. Let us unite in focus and determination to deepen our understanding and develop solutions that will have a lasting impact on the lives of glioblastoma patients. Every step forward is a beacon of hope, and together, we can transform the glioblastoma landscape.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.